^
    14h
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Recruiting, West German Study Group | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Orserdu (elacestrant)
    15h
    NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=782, Active, not recruiting, NRG Oncology | Trial primary completion date: Oct 2026 --> Dec 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    1d
    AxeCan: Axelopran for Advanced Cancer in Patients Receiving Opioids (clinicaltrials.gov)
    P2, N=34, Recruiting, HealthPartners Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PGR (Progesterone receptor)
    3d
    Comparative fine-mapping of breast cancer susceptibility loci using summary statistics methods and multinomial regression. (PubMed, medRxiv)
    Fine-mapping results vary across methods, and no single approach is sufficient. The choice of L strongly influences results, and combining analytical approaches with functional validation can improve causal variant identification.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA2 (Breast cancer 2, early onset) • CREBBP (CREB binding protein) • WNT7B (Wnt Family Member 7B)
    |
    ER positive • ER negative
    6d
    ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Laura Huppert, MD, BA | Trial completion date: Jun 2029 --> Sep 2029 | Trial primary completion date: Jun 2029 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HR negative
    |
    anvatabart opadotin (JNJ-0683)
    7d
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Recruiting, Jose Pablo Leone | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    7d
    Genetic Evidence Links Gestational Diabetes Mellitus to Increased ER-Negative Breast Cancer Risk Through a Mendelian Randomization Analysis. (PubMed, Int J Endocrinol)
    Comprehensive sensitivity analyses supported these findings. This study provides further evidence that GDM may be a risk factor for BC, particularly the ER-negative subtype, suggesting that GDM may be incorporated into personalized risk assessment models.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    8d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Orserdu (elacestrant)
    8d
    ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer (clinicaltrials.gov)
    P2, N=111, Active, not recruiting, Dana-Farber Cancer Institute | N=82 --> 111
    Enrollment change
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 negative
    |
    Kadcyla (ado-trastuzumab emtansine)
    13d
    Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • capecitabine
    14d
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=246, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Halaven (eribulin mesylate)
    15d
    FAsting-mimicking diet in combination with neoadjuvant Chemo-immunoTherapy for early or locally advanced Triple-Negative breast cancer: the prospective, single-arm, open-lable, phase 2 FACT-TN trial (ChiCTR2600118124)
    P2, N=80, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    Loqtorzi (toripalimab-tpzi)